- Regioselective Amination or Alkoxylation of Halogenated Amino-, Thio- or Alkoxypyridines via Pyridyne Intermediates
-
The treatment of 3-halopyridines (Cl, Br) bearing an R-substituent in position 2 (R = OEt, NEt2, N-piperidyl, or SEt) or in position 5 (R = OMe, OEt, SEt, NMe2, NEt2, or aryl) with KHMDS and an amine at 25 C for 12 hours in THF provided regioselectively 3
- Djukanovic, Dimitrije,Heinz, Benjamin,Idriess, Mohamed,Knochel, Paul,Martin, Benjamin,Siemens, Fiona
-
-
- COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
-
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound useful in the treatment of a neurodegenerative disorder and their combined use as a medicament, in particular for the treatment of neurodegenerative and/or cognitive disorders.
- -
-
Page/Page column 136
(2019/07/19)
-
- MACROCYCLES AS PDE1 INHIBITORS
-
The present invention provides macrocycles of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
- -
-
Paragraph 0245; 0246
(2019/06/30)
-
- 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
-
The present invention provides 1H-pyrazolo[4,3-b]pyridines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
- -
-
Paragraph 0645-0646
(2019/07/10)
-
- COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF 1H-PYRAZOLO[4,3-B]PYRIDINES
-
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.
- -
-
Page/Page column 133
(2019/07/19)
-
- 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS
-
The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
- -
-
Page/Page column 127
(2018/09/25)
-
- SUBSTITUTED TRIAZOLOPYRIDINES
-
The present invention relates to substituted triazolopyridine compounds of general formula (I); in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, as well as to intermediate compounds useful in the preparation of said compounds.
- -
-
Page/Page column 75-76
(2015/01/06)
-
- SULFONAMIDE DERIVATIVES AND USE THEREOF AS VGSC INHIBITORS
-
The invention relates to new sulfonamide Nav1.7 inhibitors and pharmaceutically acceptable salts thereof, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. Nav1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.
- -
-
Page/Page column 45
(2013/07/05)
-
- TRIAZOLOPYRIDINE DERIVATIVES
-
The present invention relates to triazolopyridine compounds of general formula (I) which are Monopolar Spindle 1 kinase (Mps-1 or TTK) inhibitors in which R1, R2, R3, R4, and R5 are as given in the description and in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of proliferative diseases, as well as to intermediate compounds useful in the preparation of said compounds.
- -
-
Page/Page column 105
(2011/06/23)
-